Brighthouse Financial Announces Cash Tender Offer for 3.700% and 4.700% Senior Notes
Brighthouse Financial, Inc. (BHF) has launched a cash tender offer for up to
- The cash tender offer can lead to lower interest expenses if the refinancing is successful.
- The offer allows the company to manage its debt strategy effectively.
- The tender offer is contingent on raising at least
$500 million from debt or preferred stock financings, which poses a risk if unmet. - Potential investor dilution may occur if additional securities are issued to meet financing conditions.
Title of
|
CUSIP
|
Principal
|
Acceptance
|
Reference
|
Bloomberg
|
Fixed Spread
|
Early Tender
|
Hypothetical
|
|
10922NAC7/
|
|
1 |
|
PX1 |
50 |
|
|
|
10922NAF0/
|
|
2 |
|
PX1 |
175 |
|
|
(1) |
The applicable page on Bloomberg from which the Dealer Managers will quote the bid side prices of the applicable |
(2) |
Per |
(3) |
The Total Consideration for each series of Notes, which will be determined as set forth in the Offer to Purchase, will be inclusive of the Early Tender Premium but exclusive of Accrued Interest and will be based on the fixed spread specified above plus the Reference Yield of the Reference |
All documentation relating to the Offer, including the Offer to Purchase and the Letter of Transmittal, together with any updates, are available from the Information Agent and the Tender Agent, as set forth below. The Tender Offer Documents set forth a complete description of the terms and conditions of the Offer. Holders are urged to read the Tender Offer Documents carefully before making any decision with respect to the Offer.
Purpose of the Offer
The purpose of the Offer is to refinance the Notes that are validly tendered and accepted for purchase in the Offer.
Details of the Offer
The Offer will expire at
Notes may be withdrawn at or prior to, but not after,
The “Total Consideration” per
The amount of Notes of either series that the Company will purchase in the Offer on the applicable Settlement Date will be determined in accordance with the Acceptance Priority Levels as set forth in the table above, with Acceptance Priority Level 1 being the highest Acceptance Priority Level, and will be the greatest amount such that the aggregate purchase price (including principal and premium, but excluding Accrued Interest) of all Notes purchased in the Offer does not exceed the Tender Cap. Subject to applicable law, the Company expressly reserves the right, but is not obligated, to increase, decrease or eliminate the Tender Cap in its sole discretion without extending the Early Tender Deadline or the Withdrawal Deadline or otherwise reinstating withdrawal rights. If any Notes are accepted for purchase, all 2027 Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline will, subject to the Tender Cap, be accepted for purchase before any 2047 Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline are accepted for purchase pursuant to the Offer. If any Notes tendered after the Early Tender Deadline are accepted for purchase, then all 2027 Notes validly tendered and not validly withdrawn after the Early Tender Deadline and at or prior to the Expiration Date will, subject to the Tender Cap, be accepted for purchase before any 2047 Notes validly tendered and not validly withdrawn after the Early Tender Deadline and at or prior to the Expiration Date are accepted for purchase pursuant to the Offer. However, any Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline will, subject to the Tender Cap, be accepted for purchase in priority to all Notes validly tendered and not validly withdrawn after the Early Tender Deadline and at or prior to the Expiration Date. If the aggregate purchase price (including principal and premium, but excluding Accrued Interest) of the Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline equals or exceeds the Tender Cap, no Notes of any series validly tendered and not validly withdrawn after the Early Tender Deadline and at or prior to the Expiration Date will be accepted for purchase, regardless of the Acceptance Priority Level of such Notes. As such, we cannot assure you that any or all tendered Notes of a given Acceptance Priority Level will be accepted for purchase.
If the aggregate purchase price (including principal and premium, but excluding Accrued Interest) of Notes of a series validly tendered results in the aggregate purchase price (including principal and premium, but excluding Accrued Interest) of validly tendered Notes of such series and all series with a higher Acceptance Priority Level (if any) exceeding the Tender Cap, the amount of such Notes purchased will be determined on a prorated basis using a single proration factor applicable equally to the Notes of that series. Depending on the amount tendered and the applicable proration factor applied, if the principal amount of Notes of a series returned to a Holder as a result of proration would result in less than the minimum authorized denomination of
Payment for Notes that are validly tendered and not validly withdrawn at or prior to the Early Tender Deadline and accepted for purchase will be made promptly following such Early Tender Deadline on the Early Settlement Date. The Company anticipates that the Early Settlement Date will be
If you validly tender your Notes at or prior to the Withdrawal Deadline, you may validly withdraw those tendered Notes at any time at or prior to the Withdrawal Deadline, but not thereafter, except in certain limited circumstances where additional withdrawal rights are required by law (as determined by the Company in its sole discretion). In the event the Offer is terminated, any Notes tendered pursuant to the Offer will be promptly returned. Notes tendered pursuant to the Offer and not purchased due to Acceptance Priority Levels, proration or a defect in the tender will be returned to the tendering Holders promptly following the Expiration Time.
The Offer is subject to the satisfaction or waiver of the conditions, including, without limitation, the receipt by the Company prior to the Expiration Time of gross proceeds of at least
None of the Company, the Company's Board of Directors, the Dealer Managers, the Tender Agent, the Information Agent, the trustee under the indenture governing the Notes or any of their respective affiliates is making any recommendation as to whether Holders should tender any Notes in response to the Offer. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amounts of Notes to tender.
This press release shall not constitute an offer to sell, a solicitation of an offer to buy, or an offer to purchase any securities. The Offer is being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law.
Forward-Looking Statements
This news release and other oral or written statements that we make from time to time may contain information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements using words such as "anticipate," "estimate," "expect," "may," "will," "could," "intend," "believe" and other words and terms of similar meaning.
Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of the Company. These statements are based on current expectations and the current economic environment and involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others: differences between actual experience and actuarial assumptions and the effectiveness of our actuarial models; higher risk management costs and exposure to increased market risk due to guarantees within certain of our products; the effectiveness of our variable annuity exposure risk management strategy and the impact of such strategy on volatility in our profitability measures and negative effects on our statutory capital; material differences from actual outcomes compared to the sensitivities calculated under certain scenarios and sensitivities that we may utilize in connection with our variable annuity risk management strategies; the impact of interest rates on our future ULSG policyholder obligations and net income volatility; the impact of the COVID-19 pandemic; the potential material adverse effect of changes in accounting standards, practices or policies applicable to us, including changes in the accounting for long-duration contracts; loss of business and other negative impacts resulting from a downgrade or a potential downgrade in our financial strength or credit ratings; the availability of reinsurance and the ability of the counterparties to our reinsurance or indemnification arrangements to perform their obligations thereunder; heightened competition, including with respect to service, product features, scale, price, actual or perceived financial strength, claims-paying ratings, credit ratings, e-business capabilities and name recognition; our ability to market and distribute our products through distribution channels; any failure of third parties to provide services we need, any failure of the practices and procedures of such third parties and any inability to obtain information or assistance we need from third parties; the ability of our subsidiaries to pay dividends to us, and our ability to pay dividends to our shareholders and repurchase our common stock; the adverse impact on liabilities for policyholder claims as a result of extreme mortality events; the impact of adverse capital and credit market conditions, including with respect to our ability to meet liquidity needs and access capital; the impact of economic conditions in the capital markets and the
Any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as otherwise may be required by law.
About
1 Ranked by 2020 admitted assets. Best’s Review®: Top 200 U.S. Life/Health Insurers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006060/en/
For Investors:
(980) 949-3073
damante@brighthousefinancial.com
For Media:
(980) 949-3071
deon.roberts@brighthousefinancial.com
Source:
FAQ
What is the purpose of Brighthouse Financial's tender offer?
When does the tender offer for Brighthouse Financial expire?
What is the total amount Brighthouse Financial is looking to raise in its tender offer?
What are the early tender deadlines for Brighthouse Financial's offer?